Patients missing out on optimum therapy post-MI: Aust study

A big data linkage study shows low rates of dispensing post-discharge and wide variation among hospitals

Almost half the patients hospitalised for acute MI miss out on guideline-recommended dual antiplatelet therapy upon discharge, an Australian study has found.

And among those who were given a P2Y12 inhibitor — clopidogrel, ticagrelor or prasugrel — within one month of leaving hospital, one quarter discontinued the therapy within 12 months, the researchers say.

The UNSW Sydney-led team analysed data from 31,800 patients (median age 68) discharged from NSW and Victorian public hospitals from 2011 to 2013 with a primary